I D
× COVER STORYIN THE NEWSNEWSFRONTSCHEMENTATOR + Show More
Chemical EngineeringChementator briefs
Toxicology testing The world’s first toxicology-testing strategy without animal testing…
BUSINESS NEWSTECHNICAL & PRACTICALFEATURE REPORTFACTS AT YOUR FINGERTIPSTECHNOLOGY PROFILESOLIDS PROCESSINGENVIRONMENTAL MANAGEREQUIPMENT & SERVICESFOCUS
Focus on Software
Enterprise-level software simplifies data management Last month, this company launched…
NEW PRODUCTS + Show More SHOW PREVIEWS

Comment uncategorized

Thermo Fisher Scientific plans $600-million bioprocessing expansion

By Mary Page Bailey |

Thermo Fisher Scientific Inc. (Waltham, Mass.) announced plans to invest more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022. These investments are expected to more than double the company’s current manufacturing capacity and support biopharma customers as they ramp up to meet both the short-term demands related to COVID-19 as well as long-term efforts to develop new vaccines and biologics for other conditions.

“As the bioprocessing market grows, our customers require a consistent and reliable supply of critical materials. Single-use technologies, cell culture media and purification resins are among those in highest demand,” said Michel Lagarde, executive vice president of Thermo Fisher Scientific. “These investments add significant capacity and regional redundancy to further bolster supply chains and help us better support customers as they accelerate the commercialization of lifesaving therapies and vaccines.” 

With these investments, the company expects to create more than 1,500 new jobs across 11 manufacturing sites in the Americas, Europe and Asia. Specific investments include:

Single-Use Technologies Expansions

To increase supply chain resiliency across multiple locations on three continents, Thermo Fisher’s single-use technologies business is expanding capacity at sites in Logan, Utah; Millersburg, Pa.; Cramlington, U.K.; Singapore and Suzhou, China.  Additional investment at its Santa Clara, Calif. site will expand bioprocessing equipment and automation capacity.

Purification Expansions

The company will also expand its state-of-the-art POROS resin manufacturing site in Bedford, Mass. and open a new 85,000-square-foot manufacturing facility in Chelmsford, Mass. Together, these sites will reinforce Thermo Fisher’s purification network that specializes in the production of process-scale chromatography resins for a variety of applications, including vaccines and gene therapies.

Cell Culture Media and Process Liquid Expansions

Investments to expand capacity at sites in Grand Island, N.Y.; Miami, Fla. and Inchinnan, Scotland will increase production of Gibco cell culture media, supplements and process liquids as well as the manufacturing of customer-owned proprietary media formulations. These investments provide redundancy to support global supply and further extend capabilities, including harmonizing dual-milling options worldwide. 

Related Content

Chemical Engineering publishes FREE eletters that bring our original content to our readers in an easily accessible email format about once a week.
Subscribe Now
Steel Belt Units for Medical Membranes
Upstream Oil & Gas: Automation intelligence from wellhead to distribution
Video - CoriolisMaster
Video - Do you really need a thermowell?
The influence of IIoT in the dewatering process step of pigment production

View More